Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells in 13 patients with R/R DLBCL reported a 92.3% objective response rate with manageable safety.
This review synthesizes evidence on the role of RNA-binding protein G3BP2 in conferring venetoclax resistance in AML through stabilizing ELF1 mRNA and upregulating MCL1 transcription, highlighting novel therapeutic avenues combining G3BP2 i
In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg
The GRAALL-2014/B-QUEST study demonstrates that integrating blinatumomab into consolidation and maintenance therapy significantly improves outcomes for adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukem
This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isofo
MDM4 haploinsufficiency activates p53, causing diverse bone marrow failure phenotypes and hypocellular MDS, highlighting the pivotal MDM4-p53 axis in hematopoietic regulation and potential targets for intervention.
Dual resistance to asparaginase and PD-1 inhibitors in extranodal NK/T-cell lymphoma leads to poor prognosis; chidamide-containing regimens show promising survival benefits in this difficult-to-treat population.
This study reveals that specific gene mutations and cardiovascular risk factors significantly influence prognosis and thrombotic risk in triple-negative essential thrombocythemia, highlighting the importance of molecular profiling for perso
FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.
Software-assisted response evaluation at six months reliably predicts survival outcomes in chronic graft-versus-host disease, offering a promising tool to guide treatment decisions and improve patient prognosis.
Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended
This retrospective matched-pair study compares fludarabine combined with treosulfan or total body irradiation as conditioning regimens before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia, finding no significant
Comprehensive genetic screening of triple negative thrombocytosis reveals germline MPL compound mutations and truncating SH2B3/LNK alterations, offering new insights into diagnosis and personalized management.
The MAIPI deep learning model offers a novel, accurate prognosis tool for mantle cell lymphoma, using standard H&E stained biopsy images, bypassing need for molecular tests or expert pathology, and enhancing risk stratification for indi
This study refines the classification of PIEZO1 variants using integrative genomic and phenotypic data, enhancing diagnosis and personalized management of hereditary red blood cell and iron disorders like dehydrated hereditary stomatocytosi
This cohort study reveals that clonal hematopoiesis of indeterminate potential (CHIP) independently increases age-related macular degeneration (AMD) risk, with amplified effects when combined with high genetic susceptibility, especially in
This study introduces CHIME, a novel HLA eplet mismatch model, revealing its association with non-relapse mortality and severe aGvHD in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide, improving
Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particula
This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.
Recent findings identify a prevalent subset of platelet-activating antibodies in HIT that evade traditional PF4/heparin ELISA detection, highlighting new diagnostic and pathogenic insights.
Open language-specific specialty feeds and department pages.